Federal Circuit Weighs Allergan’s Patent Protection Deal With Indian Tribe

Attorneys for both Allergan and Mylan faced pointed questions earlier this month from Federal Circuit judges, who are now tasked with deciding whether Allergan’s sale of its drug patents to a Native American tribe can shield those patents from inter partes review. Two of the three judges focused much of their questioning on Allergan’s motives and how a proliferation of similar deals could hurt the IRP system -- leading one attorney to predict Allergan will lose the case, though they...